Eli Lilly sues Strive and Empower as FDA lifts tirzepatide shortage status
Eli Lilly is escalating its legal push to protect the exclusivity of its high-profile weight-loss and diabetes drugs, ...
MedPage Today10m
Switch to Tirzepatide in T2D More Effective Than Upping Dulaglutide Dose
Diabetes patients on dulaglutide (Trulicity) had better glycemic control and more weight loss if they switched to tirzepatide (Mounjaro) rather than increasing the dose of the earlier-generation GLP-1 ...
Eli Lilly weight loss therapy added to Hims & Hers platform (update)
Shares of Hims & Hers Health (NYSE:HIMS) traded higher on Tuesday after the telehealth company announced the addition of ...
Eli Lilly is coming after makers of copycat versions of Zepbound
Eli Lilly (LLY) is taking legal action against makers of off-brand versions of its blockbuster diabetes and weight-loss drugs ...
Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...
Switching from dulaglutide to tirzepatide improves HbA1c reduction in type 2 diabetes
For patients with inadequately controlled type 2 diabetes receiving dulaglutide, switching to tirzepatide is associated with additional hemoglobin A1c (HbA1c) reduction and weight loss compared with ...
Medscape7h
Switching to Tirzepatide Outweighs Upping Dulaglutide Dose
The study finds better A1c lowering and weight reduction, but an expert clinician says practical issues may pose barriers.
Where Will Eli Lilly Be in 1 Year?
Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...
Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors
Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...